LOGO - Color (1).jpg
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Successful Submission of Pre-IND Meeting Request to FDA for EL-22, a Potential Breakthrough Obesity Therapy Targeting Fat Loss and Muscle Preservation in Combination with GLP-1 Receptor Agonists
February 18, 2025 07:00 ET | PMGC Holdings Inc.
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., Announces Pre-Investigational New Drug Meeting Submission Request to U.S. Food and Drug A
LOGO - Color (1).jpg
Northstrive Biosciences, Inc., a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservation used in Combination with GLP-1
February 04, 2025 08:00 ET | PMGC Holdings Inc.
Northstrive Biosciences, a Subsidiary of PMGC Holdings Inc., Reports Positive Updates for Obesity Drug Candidates Targeting Fat Loss and Muscle Preservatio
LOGO - Color (1).jpg
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium
January 24, 2025 08:00 ET | PMGC Holdings Inc.
Northstrive Biosciences Inc., a Subsidiary of PMGC Holdings Inc., to Present Breakthrough Muscle Preservation Asset at Exclusive UCLA Obesity Symposium
800 px horizontal logo.png
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscle Preservation
December 09, 2024 08:00 ET | Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Announces FDA Regulatory Pathway for EL-22, a Pioneering Obesity Therapy Targeting Fat Loss and Muscl
800 px horizontal logo.png
CORRECTION - Elevai Labs Inc.
November 14, 2024 14:35 ET | Elevai Labs Inc.
/CORRECTION/ Elevai Labs Inc. Reports Financial Results for the Third Fiscal Quarter of 2024 and Provides Business Update
800 px horizontal logo.png
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
November 14, 2024 09:08 ET | Elevai Labs Inc.
Elevai Labs Inc. Reports Financial Results for the Second Fiscal Quarter of 2024 and Provides Business Update
800 px horizontal logo.png
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Engages Leading Contract Research Organization (CRO) to Support Regulatory Planning Efforts and Pre-IND Meeting with the Food and Drug Administration For EL-22 For The Treatment of Obesity
October 22, 2024 09:54 ET | Elevai Labs Inc.
Elevai Biosciences Engages Leading CRO to Support Regulatory Planning Efforts and Pre-IND Meeting with the FDA for EL-22 For The Treatment of Obesity
800 px horizontal logo.png
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Blocker, For the Treatment of Obesity
October 21, 2024 07:30 ET | Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Highlights Past Positive Preclinical Data Showing Potential of EL-32, A Dual Myostatin & Activin-A Bl
800 px horizontal logo.png
REPEAT: Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
October 03, 2024 15:45 ET | Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,
800 px horizontal logo.png
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients, Including GLP-1 Receptor Agonist Combinations
October 03, 2024 07:30 ET | Elevai Labs Inc.
Elevai Biosciences, a Subsidiary of Elevai Labs Inc., Expands Patent Portfolio with Two New Filings for EL-22 in Muscle Loss Treatment for Obese Patients,